Agenus announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme treated with Prophage Series G-100 in combination with the current standard of care showed an almost 18 month median progression free survival, which represents a 160% increase versus current standard of care alone. This analysis confirms continuation of the positive trends from the Phase 2 HSPPC-96 newly diagnosed GBM trial first reported at the 81st American Association of Neurological Surgeons Annual Scientific Meeting in May. Based on these findings, Agenus plans to hold an end of Phase 2 meeting with the US Food and Drug Administration to discuss a Phase 3 trial that could potentially lead to marketing approval of the HSPPC-96 vaccine as a treatment for patients with newly diagnosed GBM.
- Pharmaceuticals & Drug Trials
- glioblastoma multiforme